Printer Friendly

InflaRx downgraded to Market Perform on HS study results at Raymond James.

As previously reported, Raymond James analyst Steven Seedhouse downgraded InflaRx (IFRX) to Market Perform from Outperform as it is now trading below cash and thereby baking in what he believes is an appropriate value, which is zero value for hidradenitis suppurativa and risk to all follow-on indications in the pipeline for IFX-1. The analyst acknowledges that HS may not be a viable indication for C5a pathway inhibition, which seems "quite clear from InflaRx's failed study." Seedhouse adds that there is "obvious negative read-through" to Chemocyntrx (CCXI), which is running a large Phase 2 randomized study in HS for avacopan. He expects that study to at a minimum fail or maybe even be stopped early given the complete lack of signal demonstrated by IFX-1.

COPYRIGHT 2019 The Fly
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:The Fly
Article Type:Clinical report
Date:Jun 5, 2019
Previous Article:Del Friscos options volume is 9X daily average and puts lead calls 20:1.
Next Article:Treasury Market Summary.

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |